 Shares of Moderna Inc. MRNA, 2.39 were up 2.5 in trading on Monday afternoon after the Wall Street Journal reported that the company is considering pricing its COVID-19 vaccine at 110 to 130 per dose. Thats the same price range that Pfizer Inc. PFE, -4.57 and BioNTech BNTX, -0.11 suggested for their COVID vaccine once the COVID vaccines move into a commercial market. 